Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614097 | 0.90 | RORC (0.37) | RORCMTNR1B | |
| Hydrochloric Acid SCHEMBL3602849 | 0.85 | RORC (0.36) | RORCGHSRMTNR1B | |
| SCHEMBL3610576 | 0.84 | GHSR (0.40) | RORCGHSRDRD2 | |
| SCHEMBL3612271 | 0.83 | KMT2A (0.36) | RORCMTNR1B | |
| SCHEMBL3595620 | 0.82 | RORC (0.38) | RORCGHSRMTNR1B | |
| SCHEMBL3605281 | 0.81 | GHSR (0.47) | GHSR | |
| SCHEMBL3602757 | 0.80 | HRH3 (0.40) | RORC | |
| SCHEMBL3616055 | 0.80 | RORC (0.38) | RORCMTNR1B | |
| SCHEMBL3607481 | 0.79 | TMEM97 (0.37) | MTNR1B | |
| Hydrochloric Acid SCHEMBL3604710 | 0.78 | RORC (0.36) | RORCMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | RORC 488/4885NR1I3 732/4885GHSR 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.